Corcept Therapeutics Incorporated (CORT)
Corcept präsentiert Ergebnisse der Phase-2-Studie mit Dazucorilant bei Patienten mit amyotropher Lateralsklerose (ALS) auf der ENCALS-Jahrestagung 2025
Corcept Therapeutics Incorporated (CORT)
Corcept présente les résultats dune étude de phase 2 évaluant le dazucorilant chez les patients atteints de sclérose latérale amyotrophique (SLA) lors de la réunion annuelle 2025 de lENCALS
9 Meters Biopharma, Inc. (NMTRQ)
Intel Arc Battlemage: What’s Next for the Lineup
Fortrea Holdings Inc (FTRE)
Deadline Approaching: Fortrea Holdings Inc. (FTRE) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
9 Meters Biopharma, Inc. (NMTRQ)
Best AirPods Alternatives That Deliver Quality Without High Prices
9 Meters Biopharma, Inc. (NMTRQ)
Wicked: For Good Trailer Drops – A Glimpse Into the Sequel
9 Meters Biopharma, Inc. (NMTRQ)
Marvel Tōkon: Fighting Souls Announced At State Of Play – Gaming Coming 2026
9 Meters Biopharma, Inc. (NMTRQ)
Spider-Man: Beyond the Spider-Verse – New Release Date, Teasers, and What to Expect
Treace Medical Concepts Inc. (TMCI)
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology
Urogen Pharma Inc (URGN)
URGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit